MedTrace Logo

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

NCT05224661 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 303

Last updated 2026-01-13

No results posted yet for this study

Summary

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

Conditions

  • Acute Myeloid Leukemia in Remission

Interventions

OTHER

Prospective determination of the clinical utility of measurable residual disease (MRD) testing

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

Sponsors & Collaborators

Principal Investigators

  • Christopher Hourigan, DM, D.Phil. · Virginia Polytechnic Institute and State University

  • Jeffrey Auletta, MD · National Marrow Donor Program

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-26
Primary Completion
2029-07-01
Completion
2029-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05224661 on ClinicalTrials.gov